Labcorp Q1 revenue $3.35B (+5.3% YoY), adj. EPS $3.84 vs $3.68; raises midpoint of FY adj. EPS guidance

LABCORP HOLDINGS INC.

2025-Q1 EPS reported $2.52 revenue$3,345,100,000

Revenue $3.35B, GAAP diluted EPS $2.52 (down from $2.69), adjusted EPS $3.84 (up from $3.68).
Raised adjusted EPS guidance midpoint to $15.70–$16.40; revenue and free cash flow guidance reaffirmed.
Diagnostics segment revenue $2.63B (+6.0%), adjusted operating margin 16.3% (down 60bps due to Invitae and weather).
Biopharma segment revenue $721.3M (+1.5%), adjusted operating margin 14.8% (up 80bps).
Announced acquisitions of BioReference Health oncology assets and Inspira Health lab management; new liquid biopsy test Labcorp Plasma Complete.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.